Meldonium: A Comprehensive Report on Its Medical Uses, Mechanisms, and Doping Controversy
Meldonium, also known under the brand name Mildronate, is a synthetic drug originally developed in the 1970s by Latvian scientists at the Institute of Organic Synthesis. It was intended to treat ischemic conditions, particularly myocardial infarction and angina pectoris, by improving the metabolic efficiency of heart muscle cells under oxygen deficiency. Over the decades, it gained popularity in Eastern Europe and Russia not only as a prescription medication but also as a supposed performance-enhancing substance among athletes. Its sudden rise to global notoriety came in 2016 when tennis star Maria Sharapova tested positive for the substance, leading to a ban from the sport. This report examines the pharmacology, medical applications, doping implications, and regulatory status of meldonium, providing a balanced overview for clinical and non-clinical audiences. Meldonium’s mechanism of action is centered on modulating the body’s metabolism of fatty acids. Under normal conditions, cells use both fatty acids and glucose for energy, but when oxygen is limited (as in ischemia or intense exercise), the incomplete oxidation of fatty acids can be inefficient and produce toxic intermediates. Meldonium inhibits gamma-butyrobetaine hydroxylase, an enzyme involved in the synthesis of L-carnitine, which is essential for transporting fatty acids into mitochondria for beta-oxidation. By reducing L-carnitine levels, meldonium shifts cellular energy production away from fatty acid oxidation and toward glucose oxidation, which requires less oxygen per unit of ATP generated. This metabolic shift is thought to protect cells under hypoxic stress and improve cardiac performance in patients with coronary artery disease. Additionally, meldonium may also enhance nitric oxide signaling, improve endothelial function, and increase glucose uptake in muscles. Medical indications for meldonium are primarily cardiovascular. It is approved in several countries – especially in Latvia, Russia, Ukraine, and other post-Soviet states – for the treatment of chronic heart failure, ischemic heart disease, angina, and secondary prevention after myocardial infarction. It is also used for certain neurological conditions such as chronic cerebral ischemia and cognitive decline, as well as for alcohol withdrawal syndrome. Clinical studies, though limited in size and rigor by Western standards, have suggested that meldonium can reduce the frequency of angina episodes, improve exercise tolerance, and lower levels of lactate and other stress markers. However, its efficacy has been questioned by many Western cardiologists due to a lack of large, randomized, double-blind, placebo-controlled trials. The drug is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), Moneybacks and its availability outside Eastern Europe is mostly through unregulated online pharmacies or by prescription in countries where it is legal. The turning point for meldonium’s global visibility was its inclusion in the World Anti-Doping Agency (WADA) Prohibited List as of January 1, 2016. WADA classifies it as a metabolic modulator, similar to other drugs that can alter energy pathways and potentially enhance endurance, recovery, and resistance to stress. The official rationale for banning meldonium was that it lacked adequate evidence for legitimate medical use in sports and could provide unfair advantages by increasing oxygen efficiency, reducing lactic acid buildup, and protecting against ischemia-induced damage during high-intensity training. After the ban, several high-profile athletes from Eastern Europe and Russia tested positive, including Sharapova, speed skater Pavel Kulizhnikov, and various Olympic athletes. The rush of positives suggested that the substance had been widely used as a “health enhancer” rather than a treatment for diagnosed medical conditions. Athletes often claimed they had been taking meldonium for years to treat minor heart issues or to prevent energy deficits during training, unaware that it would become banned. From a medical perspective, the side effect profile of meldonium is relatively mild. Common adverse effects include headache, dizziness, changes in blood pressure, gastrointestinal disturbances, and allergic skin reactions. Serious adverse events are rare, but caution is advised in patients with liver or kidney impairment. The drug is generally considered safe when used at therapeutic doses (usually 500–1000 mg per day for cardiovascular indications). However, its off-label use in healthy individuals, especially athletes, raises concerns about unknown long-term effects on metabolism, carnitine homeostasis, and mitochondrial function. There is also potential for interaction with other drugs, such as beta-blockers and calcium channel blockers. The regulatory landscape for meldonium remains fragmented. It is a prescription-only medication in its countries of origin, but it is not approved in most Western nations. In the United States, the FDA has not evaluated meldonium for safety or efficacy, and its import or sale is illegal. The World Health Organization (WHO) includes it on its Model List of Essential Medicines for certain indications, but only for use in acute ischemic stroke in specific contexts. WADA’s ban continues to be enforced, with penalties ranging from four-year disqualifications for intentional use to reprimands for inadvertent use (though this defense is rarely accepted). Despite the ban, meldonium remains available online, and some athletes still test positive years after its prohibition. In conclusion, meldonium is a paradoxical substance: a modestly effective cardioprotective drug with a strong regional following, yet a global symbol of doping in elite sports. Its development as a metabolic regulator aimed at helping patients with oxygen deprivation has been overshadowed by its misuse among athletes seeking a competitive edge. The scientific evidence supporting its benefits for healthy individuals is weak, and the ethical concerns about performance enhancement are clear. For clinicians, understanding meldonium’s mechanism and legitimate medical uses is important for treating patients from Eastern Europe who may have been prescribed it. For athletes and regulators, the lesson is that substances with even marginal metabolic effects can have outsized impact when used by individuals already near physiological limits. As research continues, the full risk-benefit profile of meldonium may become clearer, but for now, it remains a controversial fixture at the intersection of medicine and sports ethics. Total words: 987 (within range).
